Natco Pharma, 524816, NATCOPHARM Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

15,670.32
9.23
2

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

13,767.42
0.69%
1.94

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

17.09
15.86
27.16

EBITDA CAGR (%)

10 Years
5 Years
3 Years

23.43
24.62
46.06

PAT CAGR (%)

10 Years
5 Years
3 Years

26.28
24.68
101.38

P:E (Median)

8 Years
5 Years
3 Years

21.68
25.50
15.41

P:BV (Average)

8 Years
5 Years
3 Years

3.58
3.22
2.81

EV:EBITDA (Average)

8 Years
5 Years
3 Years

16.65
17.72
11.19

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 77.34 105.26 109.76 38.58
P/E Ratio 11.31 8.31 7.97 22.68
Revenue 3999 4430 5069 3449
EBITDA 1751 2338 788
Net Income 1388 1885 1917 693
ROA 22.1 21.5 6.9
P/B Ratio 2.80 1.72 1.61
ROE 25.88 24.87 8.25
FCFF 913 1481 901
FCFF Yield 6.33 10.27 6.25
Net Debt -1025
BVPS 312.23 510.05 544.03

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,192.70 1,236.90 -3.57% 1,157.40 964.80 19.96% 407.60 625.30 -34.82% 1,292.60 930.50 38.91%
Expenses 653.00 473.90 37.79% 596.20 512.10 16.42% 378.20 387.00 -2.27% 501.90 488.20 2.81%
EBITDA 539.70 763.00 -29.27% 561.20 452.70 23.97% 29.40 238.30 -87.66% 790.70 442.30 78.77%
EBIDTM 45.25% 61.69% 48.49% 46.92% 7.21% 38.11% 61.17% 47.53%
Other Income 59.60 39.80 49.75% 62.10 35.90 72.98% 168.00 29.50 469.49% 51.40 24.70 108.10%
Interest 2.60 4.40 -40.91% 8.80 4.50 95.56% 3.40 3.80 -10.53% 3.00 3.00 0.00%
Depreciation 53.80 40.40 33.17% 93.70 51.60 81.59% 43.70 40.40 8.17% 42.20 40.00 5.50%
PBT 542.90 758.00 -28.38% 520.80 432.50 20.42% 150.30 223.60 -32.78% 796.90 424.00 87.95%
Tax 78.80 121.70 -35.25% 92.70 83.40 11.15% 25.40 31.60 -19.62% 135.80 63.80 112.85%
PAT 464.10 636.30 -27.06% 428.10 349.10 22.63% 124.90 192.00 -34.95% 661.10 360.20 83.54%
PATM 38.91% 51.44% 36.99% 36.18% 30.64% 30.71% 51.15% 38.71%
EPS 25.91 35.53 -27.08% 23.90 19.49 22.63% 6.97 10.72 -34.98% 36.91 20.11 83.54%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 1,328.90 1,362.60 -2.47% 1,221.00 1,068.30 14.29% 474.80 758.60 -37.41% 1,371.10 1,031.40 32.94%
Expenses 757.90 557.80 35.87% 672.90 571.00 17.85% 436.00 490.50 -11.11% 566.80 573.40 -1.15%
EBITDA 571.00 804.80 -29.05% 548.10 497.30 10.22% 38.80 268.10 -85.53% 804.30 458.00 75.61%
EBIDTM 42.97% 59.06% 44.89% 46.55% 8.17% 35.34% 58.66% 44.41%
Other Income 61.70 48.10 28.27% 66.30 42.00 57.86% 176.30 37.00 376.49% 63.80 29.40 117.01%
Interest 3.20 5.20 -38.46% 10.20 6.20 64.52% 4.40 4.60 -4.35% 4.10 4.20 -2.38%
Depreciation 57.60 44.10 30.61% 98.30 55.50 77.12% 47.00 44.20 6.33% 45.80 43.60 5.05%
PBT 571.90 803.60 -28.83% 505.90 477.60 5.93% 163.70 256.30 -36.13% 818.20 439.60 86.12%
Tax 91.60 135.10 -32.20% 99.90 91.30 9.42% 31.30 43.60 -28.21% 141.70 70.60 100.71%
PAT 480.30 668.50 -28.15% 406.00 386.30 5.10% 132.40 212.70 -37.75% 676.50 369.00 83.33%
PATM 36.14% 49.06% 33.25% 36.16% 27.89% 28.04% 49.34% 35.78%
EPS 26.85 37.35 -28.11% 22.72 21.58 5.28% 7.43 11.88 -37.46% 37.84 20.61 83.60%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 4,050.30 3,568.90 2,351.00 1,767.80 1,653.50 1,790.20 1,986.30 2,091.30 1,958.00 1,021.40 715.55 Net Sales Growth 7.79% 51.80% 32.99% 6.91% -7.64% -9.87% -5.02% 6.81% 91.70% 42.74% Cost Of Goods Sold 631.40 525.80 485.60 502.10 472.30 369.80 317.60 388.50 572.80 256.30 170.70 Gross Profit 3,418.90 3,043.10 1,865.40 1,265.70 1,181.20 1,420.40 1,668.70 1,702.80 1,385.20 765.10 544.85 GP Margin 84.41% 85.27% 79.34% 71.60% 71.44% 79.34% 84.01% 81.42% 70.75% 74.91% 76.14% Total Expenditure 2,129.30 1,931.90 1,530.20 1,554.80 1,238.30 1,212.20 1,169.80 1,162.90 1,266.00 740.70 486.99 Power & Fuel Cost - 88.90 81.90 76.40 59.40 62.40 59.60 56.10 50.50 43.70 40.49 % Of Sales - 2.49% 3.48% 4.32% 3.59% 3.49% 3.00% 2.68% 2.58% 4.28% 5.66% Employee Cost - 454.90 425.70 410.10 380.00 356.10 340.20 312.20 232.10 171.90 116.19 % Of Sales - 12.75% 18.11% 23.20% 22.98% 19.89% 17.13% 14.93% 11.85% 16.83% 16.24% Manufacturing Exp. - 341.70 269.90 340.80 160.50 230.40 257.50 175.10 134.20 100.60 65.41 % Of Sales - 9.57% 11.48% 19.28% 9.71% 12.87% 12.96% 8.37% 6.85% 9.85% 9.14% General & Admin Exp. - 253.10 155.70 122.50 92.60 111.20 103.90 96.00 78.30 56.90 48.57 % Of Sales - 7.09% 6.62% 6.93% 5.60% 6.21% 5.23% 4.59% 4.00% 5.57% 6.79% Selling & Distn. Exp. - 117.40 59.50 27.00 29.20 22.60 33.50 98.00 128.80 88.40 34.29 % Of Sales - 3.29% 2.53% 1.53% 1.77% 1.26% 1.69% 4.69% 6.58% 8.65% 4.79% Miscellaneous Exp. - 150.10 51.90 75.90 44.30 59.70 57.50 37.00 69.30 22.90 34.29 % Of Sales - 4.21% 2.21% 4.29% 2.68% 3.33% 2.89% 1.77% 3.54% 2.24% 1.58% EBITDA 1,921.00 1,637.00 820.80 213.00 415.20 578.00 816.50 928.40 692.00 280.70 228.56 EBITDA Margin 47.43% 45.87% 34.91% 12.05% 25.11% 32.29% 41.11% 44.39% 35.34% 27.48% 31.94% Other Income 341.10 104.70 109.40 94.60 103.50 123.80 129.80 39.40 13.20 12.90 13.57 Interest 17.80 14.50 8.60 13.30 11.30 20.60 18.80 14.70 17.50 21.90 30.13 Depreciation 233.40 171.90 150.90 138.40 115.20 98.10 80.10 65.50 53.60 50.20 42.46 PBT 2,010.90 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 169.54 Tax 332.70 248.70 133.60 16.80 82.70 108.60 180.30 189.40 139.30 45.00 1.48 Tax Rate 16.54% 15.99% 17.33% 10.78% 21.09% 18.62% 21.28% 21.34% 21.97% 20.32% 0.96% PAT 1,678.20 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 152.93 PAT before Minority Interest 1,678.20 1,306.60 637.10 139.10 309.50 474.50 667.10 698.20 494.80 176.50 152.93 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 41.43% 36.61% 27.10% 7.87% 18.72% 26.51% 33.59% 33.39% 25.27% 17.28% 21.37% PAT Growth 9.14% 105.09% 358.02% -55.06% -34.77% -28.87% -4.45% 41.11% 180.34% 15.41% EPS 93.70 72.95 35.57 7.77 17.28 26.49 37.25 38.98 27.63 9.85 8.54

Description TTM Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Net Sales 4,395.80 3,998.80 2,707.10 1,944.80 2,052.10 1,915.00 2,094.50 2,184.80 2,020.20 1,141.30 825.28 Net Sales Growth 4.14% 47.72% 39.20% -5.23% 7.16% -8.57% -4.13% 8.15% 77.01% 38.29% Cost Of Goods Sold 742.60 667.90 583.20 528.40 483.70 354.40 332.70 411.10 599.10 341.10 242.37 Gross Profit 3,653.20 3,330.90 2,123.90 1,416.40 1,568.40 1,560.60 1,761.80 1,773.70 1,421.10 800.20 582.90 GP Margin 83.11% 83.30% 78.46% 72.83% 76.43% 81.49% 84.12% 81.18% 70.34% 70.11% 70.63% Total Expenditure 2,433.60 2,247.40 1,795.40 1,681.30 1,448.30 1,332.40 1,299.70 1,256.40 1,336.80 868.70 611.90 Power & Fuel Cost - 88.90 81.90 76.40 61.10 62.40 59.60 56.20 50.50 43.70 43.24 % Of Sales - 2.22% 3.03% 3.93% 2.98% 3.26% 2.85% 2.57% 2.50% 3.83% 5.24% Employee Cost - 525.00 486.70 444.80 414.90 375.00 355.90 325.60 243.20 189.60 136.92 % Of Sales - 13.13% 17.98% 22.87% 20.22% 19.58% 16.99% 14.90% 12.04% 16.61% 16.59% Manufacturing Exp. - 368.40 279.60 353.60 165.70 243.30 276.40 182.60 141.20 105.20 73.04 % Of Sales - 9.21% 10.33% 18.18% 8.07% 12.70% 13.20% 8.36% 6.99% 9.22% 8.85% General & Admin Exp. - 313.00 208.80 152.80 242.90 132.60 126.40 105.50 88.10 73.40 63.66 % Of Sales - 7.83% 7.71% 7.86% 11.84% 6.92% 6.03% 4.83% 4.36% 6.43% 7.71% Selling & Distn. Exp. - 153.00 96.10 43.70 34.40 98.10 90.00 136.90 143.20 91.60 37.36 % Of Sales - 3.83% 3.55% 2.25% 1.68% 5.12% 4.30% 6.27% 7.09% 8.03% 4.53% Miscellaneous Exp. - 131.20 59.10 81.60 45.60 66.60 58.70 38.50 71.50 24.10 37.36 % Of Sales - 3.28% 2.18% 4.20% 2.22% 3.48% 2.80% 1.76% 3.54% 2.11% 1.86% EBITDA 1,962.20 1,751.40 911.70 263.50 603.80 582.60 794.80 928.40 683.40 272.60 213.38 EBITDA Margin 44.64% 43.80% 33.68% 13.55% 29.42% 30.42% 37.95% 42.49% 33.83% 23.89% 25.86% Other Income 368.10 128.10 128.50 99.00 106.00 107.40 130.20 40.40 13.90 9.90 14.91 Interest 21.90 19.20 14.50 17.70 13.30 21.50 19.30 15.40 18.50 22.90 31.68 Depreciation 248.70 186.80 163.80 142.60 116.90 99.80 81.00 66.20 54.40 51.00 47.27 PBT 2,059.70 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 208.60 149.34 Tax 364.50 285.20 146.60 32.20 137.20 110.60 182.30 192.00 139.50 52.80 3.95 Tax Rate 17.70% 17.04% 17.01% 15.92% 23.67% 19.45% 22.11% 21.64% 22.34% 25.31% 2.94% PAT 1,695.20 1,388.30 715.30 170.00 440.90 460.80 644.40 696.20 486.00 157.10 134.62 PAT before Minority Interest 1,697.60 1,388.30 715.30 170.00 442.40 458.10 642.40 695.20 484.90 155.80 130.27 Minority Interest 2.40 0.00 0.00 0.00 -1.50 2.70 2.00 1.00 1.10 1.30 4.35 PAT Margin 38.56% 34.72% 26.42% 8.74% 21.49% 24.06% 30.77% 31.87% 24.06% 13.77% 16.31% PAT Growth 3.59% 94.09% 320.76% -61.44% -4.32% -28.49% -7.44% 43.25% 209.36% 16.70% EPS 94.65 77.52 39.94 9.49 24.62 25.73 35.98 38.87 27.14 8.77 7.52

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 5,592.30 4,702.00 4,191.90 4,091.10 3,869.50 3,563.20 3,125.40 1,699.70 1,336.30 878.99 Share Capital 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 33.23 Total Reserves 5,556.50 4,665.50 4,152.00 4,037.00 3,809.50 3,495.80 3,064.30 1,649.40 1,291.80 845.76 Non-Current Liabilities 69.00 116.90 134.90 142.90 117.50 83.10 47.00 37.70 27.90 117.53 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.28 Unsecured Loans 0.00 0.00 0.00 0.00 0.90 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 9.19 Current Liabilities 885.60 569.00 651.20 518.50 659.70 709.80 563.80 609.70 478.50 398.31 Trade Payables 183.30 182.40 141.20 139.50 234.20 201.80 245.40 251.40 270.10 115.34 Other Current Liabilities 204.70 201.40 104.00 111.10 93.40 108.50 131.70 122.80 110.90 113.32 Short Term Borrowings 363.20 159.90 389.00 255.10 313.10 384.50 173.00 220.60 96.00 168.54 Short Term Provisions 134.40 25.30 17.00 12.80 19.00 15.00 13.70 14.90 1.50 1.11 Total Liabilities 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70 1,394.83 Net Block 2,286.70 2,233.80 2,174.20 2,005.90 1,574.50 1,214.90 1,015.30 829.00 705.60 572.74 Gross Block 3,359.50 3,157.10 2,977.80 2,678.30 2,133.70 1,678.20 1,399.60 1,151.00 975.90 783.12 Accumulated Depreciation 1,072.80 923.30 803.60 672.40 559.20 463.30 384.30 322.00 270.30 210.39 Non Current Assets 3,136.50 2,893.20 2,810.30 2,584.00 2,406.80 2,088.70 1,682.00 1,312.00 1,051.80 950.65 Capital Work in Progress 133.90 62.80 128.70 223.40 517.80 637.50 480.00 336.20 211.90 100.77 Non Current Investment 577.80 517.60 430.40 294.90 186.10 117.60 101.30 85.90 71.70 131.15 Long Term Loans & Adv. 111.50 78.80 72.40 55.60 124.30 110.40 83.10 60.40 62.00 142.47 Other Non Current Assets 26.60 0.20 4.60 4.20 4.10 8.30 2.30 0.50 0.60 3.52 Current Assets 3,410.40 2,494.70 2,167.70 2,168.50 2,239.90 2,267.40 2,054.20 1,035.10 790.90 444.18 Current Investments 163.90 139.90 119.60 42.10 5.00 126.80 48.30 8.90 22.10 0.12 Inventories 596.90 616.00 697.70 769.20 524.40 508.40 425.80 336.90 351.90 198.35 Sundry Debtors 1,076.60 793.10 575.60 399.80 536.70 491.60 606.00 468.90 255.80 188.96 Cash & Bank 864.90 412.00 100.90 262.80 54.10 262.70 172.10 25.10 40.20 7.19 Other Current Assets 708.10 57.60 78.10 95.20 1,119.70 877.90 802.00 195.30 120.90 49.57 Short Term Loans & Adv. 622.00 476.10 595.80 599.40 1,025.90 769.50 748.80 169.60 95.50 43.99 Net Current Assets 2,524.80 1,925.70 1,516.50 1,650.00 1,580.20 1,557.60 1,490.40 425.40 312.40 45.87 Total Assets 6,546.90 5,387.90 4,978.00 4,752.50 4,646.70 4,356.10 3,736.20 2,347.10 1,842.70 1,394.83

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Shareholder's Funds 5,853.10 4,873.80 4,263.60 4,121.60 3,773.50 3,489.00 3,072.20 1,649.30 1,295.70 846.05 Share Capital 35.80 36.50 36.50 36.50 36.40 36.50 36.90 34.90 34.80 33.23 Total Reserves 5,817.30 4,837.30 4,223.70 4,067.60 3,713.60 3,421.70 3,011.40 1,599.00 1,251.20 812.82 Non-Current Liabilities 61.00 100.50 135.10 142.90 117.80 83.40 47.10 37.70 28.00 119.23 Secured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 94.03 Unsecured Loans 0.00 0.00 0.00 0.00 0.90 0.00 0.00 0.00 0.00 2.99 Long Term Provisions 70.90 85.30 95.70 99.60 90.20 71.00 32.40 21.90 12.50 9.50 Current Liabilities 972.80 683.10 710.40 525.60 685.30 728.70 592.00 626.50 493.10 413.74 Trade Payables 235.50 263.80 161.80 146.20 255.40 217.00 269.10 262.70 275.60 125.30 Other Current Liabilities 238.90 227.30 126.70 99.50 95.90 109.80 133.40 127.10 114.20 118.56 Short Term Borrowings 363.20 165.00 404.00 265.80 315.00 386.30 173.20 221.60 98.40 168.54 Short Term Provisions 135.20 27.00 17.90 14.10 19.00 15.60 16.30 15.10 4.90 1.33 Total Liabilities 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70 1,384.05 Net Block 2,490.80 2,426.90 2,311.80 2,023.20 1,584.40 1,227.20 1,018.60 833.00 710.10 709.97 Gross Block 3,603.20 3,375.10 3,126.90 2,702.10 2,148.70 1,694.50 1,407.60 1,158.70 983.30 939.98 Accumulated Depreciation 1,112.40 948.20 815.10 678.90 564.30 467.30 389.00 325.70 273.20 225.82 Non Current Assets 2,863.40 2,657.10 2,622.40 2,447.10 2,262.20 1,955.90 1,584.40 1,230.30 984.70 901.08 Capital Work in Progress 137.30 64.30 129.50 223.40 518.00 637.60 480.00 336.30 211.80 128.96 Non Current Investment 95.90 87.30 104.40 151.90 83.60 19.90 8.10 0.10 0.10 1.57 Long Term Loans & Adv. 112.70 78.30 72.00 44.30 72.00 62.80 75.40 60.40 62.10 57.03 Other Non Current Assets 26.70 0.30 4.70 4.30 4.20 8.40 2.30 0.50 0.60 3.54 Current Assets 4,023.50 3,000.30 2,486.70 2,344.80 2,325.60 2,347.20 2,130.70 1,087.30 837.00 482.97 Current Investments 443.50 305.00 203.70 151.80 28.70 148.70 68.40 32.10 22.10 0.12 Inventories 700.50 742.90 762.00 798.20 558.00 529.00 438.40 348.90 357.30 220.00 Sundry Debtors 1,188.90 856.10 620.60 412.90 551.30 506.20 637.50 475.20 261.60 192.43 Cash & Bank 952.90 546.30 206.10 283.50 66.00 279.50 183.70 35.80 45.20 13.36 Other Current Assets 737.70 64.40 88.10 94.70 1,121.60 883.80 802.70 195.30 150.80 57.06 Short Term Loans & Adv. 638.20 485.60 606.20 603.70 1,030.00 776.40 749.50 169.50 125.40 40.97 Net Current Assets 3,050.70 2,317.20 1,776.30 1,819.20 1,640.30 1,618.50 1,538.70 460.80 343.90 69.23 Total Assets 6,886.90 5,657.40 5,109.10 4,791.90 4,587.80 4,303.10 3,715.10 2,317.60 1,821.70 1,384.05

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 1,196.40 784.40 57.70 183.50 422.50 698.80 476.40 329.80 189.90 124.55 PBT 1,555.30 770.70 155.90 392.20 583.10 847.40 887.60 634.10 221.50 154.41 Adjustment 150.90 85.40 118.50 58.40 45.20 12.10 74.40 99.80 81.70 62.73 Changes in Working Capital -257.80 76.70 -184.20 -190.20 -100.70 14.20 -281.20 -281.70 -68.50 -72.49 Cash after chg. in Working capital 1,448.40 932.80 90.20 260.40 527.60 873.70 680.80 452.20 234.70 144.64 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -252.00 -148.40 -32.50 -76.90 -105.10 -174.90 -204.40 -122.40 -44.80 -20.09 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -960.50 -436.60 -92.50 -3.20 -165.00 -645.20 -1,131.10 -290.60 -249.30 -147.95 Net Fixed Assets -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 -100.13 Net Investments -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 -42.37 Others -602.80 -215.70 325.30 392.90 117.50 -114.30 -683.90 9.80 17.14 -5.45 Cash from Financing Activity -237.30 -346.80 35.60 -183.10 -261.10 -52.20 652.00 -45.60 151.40 22.80 Net Cash Inflow / Outflow -1.40 1.00 0.80 -2.80 -3.60 1.40 -2.70 -6.40 92.00 -0.59 Opening Cash & Equivalents 6.90 5.90 5.10 7.90 11.50 10.10 12.80 19.20 -170.00 6.86 Closing Cash & Equivalent 5.50 6.90 5.90 5.10 7.90 11.50 10.10 12.80 -76.80 6.27

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Cash From Operating Activity 1,211.60 849.10 46.50 298.80 417.30 668.80 463.60 345.80 112.20 92.67 PBT 1,673.50 861.90 202.20 579.60 568.70 824.70 887.20 624.40 208.60 134.22 Adjustment 133.80 102.00 123.90 62.10 54.00 14.30 75.60 100.20 90.50 68.14 Changes in Working Capital -309.40 62.70 -231.40 -212.90 -97.60 8.60 -294.60 -253.00 -140.70 -85.96 Cash after chg. in Working capital 1,497.90 1,026.60 94.70 428.80 525.10 847.60 668.20 471.60 158.40 116.41 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -286.30 -177.50 -48.20 -130.00 -107.80 -178.80 -204.60 -125.80 -46.20 -23.74 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -1,032.70 -477.10 -5.30 -103.30 -167.00 -612.20 -1,115.50 -299.40 -175.50 -114.75 Net Fixed Assets -273.50 -113.40 -204.80 -250.20 -335.80 -436.10 -392.40 -299.40 -303.91 -100.13 Net Investments -84.20 -107.50 -213.00 -145.90 53.30 -94.80 -54.80 -1.00 37.47 -42.37 Others -675.00 -256.20 412.50 292.80 115.50 -81.30 -668.30 1.00 90.94 27.75 Cash from Financing Activity -246.90 -363.00 34.80 -185.70 -250.80 -50.90 650.90 -47.70 154.00 29.07 Net Cash Inflow / Outflow -68.00 9.00 76.00 9.80 -0.50 5.70 -1.00 -1.30 90.70 6.99 Opening Cash & Equivalents 131.90 111.10 25.80 19.80 28.30 21.70 23.50 24.20 -164.10 10.22 Closing Cash & Equivalent 70.40 131.90 111.10 25.80 19.80 28.30 21.70 23.50 -74.20 12.44

Financial Ratios

Consolidated /

Standalone

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 312.42 257.64 229.51 223.21 211.31 193.55 168.09 96.52 76.24 52.90 ROA 21.90% 12.29% 2.86% 6.59% 10.54% 16.49% 22.95% 23.62% 10.90% 11.90% ROE 25.38% 14.33% 3.37% 7.82% 12.86% 20.11% 29.18% 32.87% 16.00% 18.97% ROCE 29.02% 16.51% 3.79% 9.46% 14.85% 23.91% 34.58% 38.71% 18.48% 17.10% Fixed Asset Turnover 1.15 0.78 0.65 0.70 0.99 1.41 1.65 1.88 1.20 0.99 Receivable days 90.80 104.18 96.61 101.41 99.38 92.04 93.04 66.04 76.63 76.52 Inventory Days 58.90 100.00 145.29 140.07 99.81 78.34 66.02 62.77 94.81 90.45 Payable days 126.93 121.62 102.03 144.40 66.65 73.69 81.82 79.78 95.04 82.23 Cash Conversion Cycle 22.77 82.56 139.87 97.08 132.54 96.69 77.23 49.02 76.39 84.74 Total Debt/Equity 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.13 0.08 0.35 Interest Cover 108.26 90.62 12.72 35.71 29.31 46.07 61.38 37.23 11.11 6.12

Description Mar 24 Mar 23 Mar 22 Mar 21 Mar 20 Mar 19 Mar 18 Mar 17 Mar 16 Mar 15
Book Value (Rs.) 326.99 267.06 233.44 224.88 206.04 189.49 165.22 93.63 73.91 50.91 ROA 22.13% 13.29% 3.43% 9.43% 10.30% 16.02% 23.05% 23.43% 9.72% 10.10% ROE 25.88% 15.66% 4.06% 11.27% 12.71% 19.75% 29.70% 33.21% 14.62% 16.57% ROCE 30.08% 18.06% 4.86% 13.99% 14.82% 23.71% 35.28% 39.21% 18.04% 15.62% Fixed Asset Turnover 1.24 0.89 0.76 0.86 1.07 1.47 1.72 1.93 1.23 0.95 Receivable days 86.16 93.53 85.10 84.44 93.77 91.36 92.22 65.12 70.27 67.76 Inventory Days 60.81 95.32 128.47 118.77 96.38 77.28 65.25 62.41 89.35 87.33 Payable days 136.43 133.18 106.38 151.52 65.96 72.53 81.42 78.30 85.42 73.36 Cash Conversion Cycle 10.54 55.67 107.20 51.68 124.19 96.11 76.05 49.23 74.21 81.73 Total Debt/Equity 0.06 0.03 0.09 0.06 0.08 0.11 0.06 0.14 0.09 0.37 Interest Cover 88.16 60.44 12.42 44.58 27.45 43.73 58.61 34.75 10.11 5.24

Top Investors:

belgrave investment fund

life insurance corporation of india

tata mutual fund- tata equity p/e fund

akash bhansali

investor education and protection fund (iepf)

Annual Reports:

News Update:

NATCO Pharma launches Bosentan tablets for oral suspension
20th Aug 2025, 11:28 AM

The company holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Read More
Natco Pharma - Quarterly Results
12th Aug 2025, 13:42 PM

Read More
USFDA issues EIR to Natco Pharma’s Hyderabad API division
25th Jul 2025, 16:30 PM

USFDA had conducted an inspection at said facility from June 9, 2025 to June 13, 2025
Read More
Natco Pharma gets nod to incorporate wholly owned subsidiary in South Africa
24th Jul 2025, 11:00 AM

The objective of incorporation of subsidiary is to enter new geographies for growth and increased profitability.
Read More
USFDA concludes inspection at Natco Pharma’s Kothur pharma division
20th Jun 2025, 10:20 AM

On conclusion of the inspection, the Company received seven observations in the Form-483
Read More
USFDA concludes inspection at Natco Pharma’s Hyderabad API manufacturing plant
13th Jun 2025, 16:44 PM

On conclusion of the inspection, the Company received 1 observation in the Form 483
Read More

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update:

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Consolidated Figures in Rs. Crores /

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Cash Flow

Consolidated Figures in Rs. Crores /

Financial Ratios

Consolidated /

Top Investors:

Annual Reports:

News Update: